Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (51933)	5/6/2002 2:46:45 AM
From: GREENLAW4-7	Respond to of 208838

MYGN has a very large short interest as of late, and if ASCO conference has good news regarding their cancer fighting gene and drug wich I believe is in phase II trials, MYGN may be the best bounce canidate in BTK group. When I refer to their cancer gene, I am referring to the find they made last October that propelled their stock from 30 to 50 in several weeks. I believe BTK is so oversold, that some of these stocks w/ their short intersts may get a SUBSTANTIAL bounce from the conference. MYGN has the smallest float and smallest market cap. One last point HGSI's recent strength of holding its bottom tells me perhaps some of these GENO stocks are due for a bounce. The names which have most likelyhood near term in order MYGN, PDLI, and MLNM. All that said, nothing says we could not have more downside before reversal, but what BTK has going for it today is the DRUG/PHARMA stocks are also at their lows of the year. The last ttme we had both index's in such a positon, they rallied as the NASD contimued to tank. Just some thoughts regarding a decent trade.